Gilead Sciences, Inc. $GILD Shares Acquired by Bokf Na

Key Points

• Bokf Na increased its Gilead Sciences position by 18.6% in the third quarter, adding 25,388 shares and bringing its holdings to 161,849 shares valued at approximately $24.1 million. Institutional investors own 83.67% of the company.
• Analyst sentiment remains favorable overall: 23 analysts rate Gilead a Buy and six rate it a Hold, resulting in a consensus “Moderate Buy” rating and an average price target of $159.81.
• Gilead’s outlook is supported by strong HIV sales, progress in oncology and expanded access for LYVDELZI, but investors are also watching cash usage, competitive pressure and upcoming earnings for signs of execution risk.

Bokf Na boosted its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 18.6% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 161,849 shares of the biopharmaceutical company's stock after purchasing an additional 25,388 shares during the quarter. Bokf Na's holdings in Gilead Sciences were worth $24,124,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently bought and sold shares of the company. PFS Partners LLC grew its position in Gilead Sciences by 101.1% in the third quarter. PFS Partners LLC now owns 191 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 96 shares in the last quarter. Persistent Asset Partners Ltd purchased a new stake in Gilead Sciences during the second quarter valued at about $25,000. Laurel Wealth Advisors LLC bought a new stake in Gilead Sciences during the third quarter worth about $29,000. Kimelman & Baird LLC purchased a new position in shares of Gilead Sciences in the 2nd quarter worth about $25,000. Finally, Toth Financial Advisory Corp boosted its holdings in shares of Gilead Sciences by 85.5% in the 3rd quarter. Toth Financial Advisory Corp now owns 217 shares of the biopharmaceutical company's stock worth $32,000 after purchasing an additional 100 shares in the last quarter. 83.67% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

GILD has been the topic of several recent research reports. Wall Street Zen upgraded Gilead Sciences from a "hold" rating to a "buy" rating in a research report on Saturday, September 19th. Zacks Research downgraded Gilead Sciences from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, September 29th. Morgan Stanley cut their target price on Gilead Sciences from $165.00 to $163.00 and set an "overweight" rating for the company in a research note on Wednesday, October 7th. Weiss Ratings upgraded shares of Gilead Sciences from a "hold (c-)" rating to a "hold (c)" rating in a research report on Monday, September 14th. Finally, Needham & Company LLC reissued a "buy" rating and set a $170.00 price target on shares of Gilead Sciences in a research note on Wednesday, August 5th. Twenty-three research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $159.81.

Gilead Sciences Stock Up 0.1%

Shares of NASDAQ:GILD opened at $159.20 on Thursday. The stock has a fifty day simple moving average of $149.97 and a two-hundred day simple moving average of $139.33. The stock has a market capitalization of $197.40 billion, a price-to-earnings ratio of -59.63 and a beta of 0.31. Gilead Sciences, Inc. has a 12-month low of $114.02 and a 12-month high of $160.83. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, topping analysts' consensus estimates of ($7.25) by $0.50. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%. The firm had revenue of $7.80 billion for the quarter, compared to analysts' expectations of $7.40 billion. During the same period in the prior year, the firm posted $2.01 earnings per share. The company's quarterly revenue was up 10.6% on a year-over-year basis. On average, research analysts anticipate that Gilead Sciences, Inc. will post -0.48 earnings per share for the current fiscal year.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead completed negotiations with Canada’s pan-Canadian Pharmaceutical Alliance for public reimbursement of LYVDELZI (seladelpar), expanding potential access to the treatment for primary biliary cholangitis. The agreement could support adoption and add a new commercial opportunity, although the near-term financial contribution is not yet clear. Gilead Reaches Canadian Reimbursement Deal for Liver Disease Drug Lyvdelzi
• Positive Sentiment: Analyst commentary highlights strong HIV sales, momentum for the company’s newer HIV-prevention product Yeztugo, and expanding oncology prospects. A new oncology trial is being cited as a potential source of substantial upside, with one analysis characterizing GILD as potentially 50% undervalued if the program succeeds. Gilead Stock Could Be 50% Undervalued on New Oncology Trial News
• Neutral Sentiment: Investors are focused on Gilead’s third-quarter results, scheduled for after the bell Thursday. The earnings preview centers on HIV performance, Yeztugo uptake, pipeline progress, guidance, and cash generation. Results that exceed expectations could reinforce the stock’s momentum, while weak guidance could pressure the shares. Gilead Sciences Q3 2026 Earnings Preview
• Negative Sentiment: Some coverage warns that Gilead is burning through cash quickly and faces competitive pressure, creating execution risks despite its strong HIV franchise and pipeline. ETFs were also reported as net sellers, a potentially modest technical headwind. Three Big Pharma Earnings Reports to Watch

Insider Activity at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of the firm's stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $156.22, for a total transaction of $468,660.00. Following the completion of the sale, the insider directly owned 113,684 shares in the company, valued at approximately $17,759,714.48. This trade represents a 2.57% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel O'Day sold 15,000 shares of Gilead Sciences stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $147.90, for a total transaction of $2,218,500.00. Following the completion of the transaction, the chief executive officer directly owned 566,683 shares of the company's stock, valued at $83,812,415.70. This trade represents a 2.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 111,000 shares of company stock worth $15,877,860 in the last ninety days. 0.30% of the stock is currently owned by company insiders.

Gilead Sciences Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.